NTLA (STOCKS)
Intellia Therapeutics, Inc
$14.850000
+2.740000 (+22.63%)
Prev close: $12.110000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- John M. Leonard
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,084.66M
- Employees
- 598
- P/E (TTM)
- -3.43
- P/B (TTM)
- 2.35
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
10
Buy
11
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.81 | $-0.93 | +0.1221 | +13.10% |
|
Dec 2025 (Q4)
|
$-0.83 | $-0.97 | +0.1439 | +14.78% |
|
Sep 2025 (Q3)
|
$-0.92 | $-1.02 | +0.1019 | +9.97% |
|
Jun 2025 (Q2)
|
$-0.98 | $-1.04 | +0.0582 | +5.61% |
Financial Statements
| Revenues | $66.09M |
| Benefits Costs and Expenses | $479.58M |
| Costs And Expenses | $486.81M |
| Operating Expenses | $486.81M |
| Research and Development | $361.17M |
| Other Operating Expenses | $125.64M |
| Operating Income/Loss | -$420.72M |
| Income/Loss From Continuing Operations After Tax | -$394.60M |
| Income/Loss From Continuing Operations Before Tax | -$404.75M |
| Net Income/Loss | -$394.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$394.60M |
| Net Income/Loss Available To Common Stockholders, Basic | -$394.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.53 |
| Diluted Earnings Per Share | -$3.53 |
| Basic Average Shares | 334,945,000 |
| Diluted Average Shares | 334,945,000 |
| Assets | $758.78M |
| Current Assets | $466.45M |
| Noncurrent Assets | $292.33M |
| Fixed Assets | $15.52M |
| Other Non-current Assets | $276.81M |
| Liabilities | $137.84M |
| Current Liabilities | $76.45M |
| Accounts Payable | $18.80M |
| Wages | $9.32M |
| Other Current Liabilities | $48.32M |
| Noncurrent Liabilities | $61.40M |
| Equity | $620.94M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $620.94M |
| Liabilities And Equity | $758.78M |
| Net Cash Flow From Operating Activities | -$363.15M |
| Net Cash Flow From Operating Activities, Continuing | -$363.15M |
| Net Cash Flow From Investing Activities | $200.01M |
| Net Cash Flow From Investing Activities, Continuing | $200.01M |
| Net Cash Flow From Financing Activities | $110.45M |
| Net Cash Flow From Financing Activities, Continuing | $110.45M |
| Net Cash Flow | -$52.69M |
| Net Cash Flow, Continuing | -$52.69M |
| Comprehensive Income/Loss | -$395.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$395.89M |
| Other Comprehensive Income/Loss | -$102.22M |